hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06261346, orgStudyIdInfo id: 20230420, briefTitle: Plasma Rich in Growth Factors in Corneal Endothelial Transplantation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Price Vision Group, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growth factors (PRGF) for reducing postoperative endothelial cell loss. Subjects scheduled for endothelial keratoplasty will be enrolled and randomized to have the graft incubated in PRGF or not prior to graft implantation. The main outcome is the percentage central corneal endothelial cell loss 6 months after surgery., conditionsModule conditions: Fuchs' Endothelial Dystrophy, conditions: Corneal Edema, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: PRGF, outcomesModule primaryOutcomes measure: Endothelial cell loss at 6 months, secondaryOutcomes measure: Corneal endothelial cell density, secondaryOutcomes measure: Endothelial cell loss, secondaryOutcomes measure: Best corrected visual acuity, secondaryOutcomes measure: Re-bubble rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bascom Palmer Eye Institute, city: Miami, state: Florida, zip: 33136, country: United States, contacts name: Alfonso Sabater, MD, role: CONTACT, phone: 305-326-6326, email: asabater@med.miami.edu, geoPoint lat: 25.77427, lon: -80.19366, locations facility: Price Vision Group, city: Indianapolis, state: Indiana, zip: 46260, country: United States, contacts name: Marianne Price, PhD, role: CONTACT, phone: 317-814-2990, email: mprice@cornea.org, geoPoint lat: 39.76838, lon: -86.15804, hasResults: False
protocolSection identificationModule nctId: NCT06261333, orgStudyIdInfo id: 23-11519-BO, briefTitle: Quality of Life in Patients With Hemorrhagic Telangiectasia, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: University Hospital, Essen, class: OTHER, descriptionModule briefSummary: Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler's disease, is a genetic disorder that leads to abnormal blood vessel formations. It primarily affects blood vessels in the skin, mucous membranes, and internal organs. The disease can be clinically diagnosed using the Curaçao criteria (1. Positive family history of HHT, 2. Recurrent and spontaneous epistaxis, 3. Multiple typical telangiectasias, 4. Organ involvement with vascular malformations, especially in the liver, lungs, gastrointestinal tract, or brain); if a patient meets at least 3 criteria, the diagnosis of HHT can be established.Patients with HHT often have telangiectasias on their faces. Additionally, many patients suffer from anemia, which can result in a pale and potentially tired appearance. Patients with HHT may be less satisfied with their appearance due to the aesthetic changes in their faces and may also experience psychosocial impairment. To further investigate this, various validated questionnaires (FACE-Q©, PROMIS-Profile-29+2, EQ5D), as well as routinely collected clinical data (e.g., laboratory values including hemoglobin levels, Curaçao criteria, smoking status, alcohol consumption, and the Epistaxis Severity Score (ESS)) will be used., conditionsModule conditions: Hereditary Hemorrhagic Telangiectasia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Questionnaires, outcomesModule primaryOutcomes measure: Quality of Life and Patient Satisfaction measured using the FACE-Questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Departement of Otorhinolaryngology - Head and Neck Surgery University Hospital Essen, city: Essen, state: NRW, zip: 45147, country: Germany, geoPoint lat: 51.45657, lon: 7.01228, hasResults: False
protocolSection identificationModule nctId: NCT06261320, orgStudyIdInfo id: 2023-506950-18-00, briefTitle: Mesotherapy Treatment of Irritable Bowel Syndrome, acronym: MESOCOLO, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Polyclinique de l'Europe, class: OTHER, descriptionModule briefSummary: Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems.Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy.Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms., conditionsModule conditions: Inflammatory Bowel Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 27, type: ACTUAL, armsInterventionsModule interventions name: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate, outcomesModule primaryOutcomes measure: Irritable Bowel Syndrome Symptom Severity Scale(IBS-SSS), secondaryOutcomes measure: Functional Digestive Disorders Quality of Life questionnaire (FDDQL), secondaryOutcomes measure: Pain evaluation, secondaryOutcomes measure: Global satisfaction, secondaryOutcomes measure: Anxiety evaluation : Questionnaire "Hospital anxiety and depression scale", eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Polyclinique de l'Europe, city: Saint-Nazaire, zip: 44600, country: France, geoPoint lat: 47.28333, lon: -2.2, hasResults: False
protocolSection identificationModule nctId: NCT06261294, orgStudyIdInfo id: CPIP-LUN-A001, briefTitle: OncoSweep Cancer Spotlight and Spectrum Product Line, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-23, primaryCompletionDateStruct date: 2025-03-20, completionDateStruct date: 2026-03-20, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Pharus Taiwan, Inc., class: INDUSTRY, descriptionModule briefSummary: CONQUER cancer study: To collect blood samples from cancer and non-cancer participants for development and validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line', conditionsModule conditions: Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: OncoSweep Lung Spotligh, outcomesModule primaryOutcomes measure: To differentiate lung cancer signals from non-cancer signals based on analysis of OncoSweep Lung Spotlight., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mackay Memorial Hospital, status: RECRUITING, city: Taipei, state: Zhongshan Dist, zip: 104217, country: Taiwan, contacts name: Sheng-Hsiung Yang, role: CONTACT, phone: +886 2 2543-3535, email: lazatemax@gmail.com, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06261281, orgStudyIdInfo id: TBI cancel, briefTitle: Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patient, acronym: IOE-TBI, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2024-02-10, primaryCompletionDateStruct date: 2024-07-10, completionDateStruct date: 2024-07-10, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Zeng Changhao, class: OTHER, descriptionModule briefSummary: This was a multicenter randomized controlled study of 98 severe Traumatic Brain Injury patients with tracheostomy. Patients enrolled were divided randomly into the observation group with Intermittent Oro-esophageal Tube Feeding or the control group with Nasogastric tube feeding for enteral nutrition support, respectively. Nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared., conditionsModule conditions: Traumatic Brain Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 0, type: ACTUAL, armsInterventionsModule interventions name: Rehabilitation therapy, interventions name: Intermittent Oro-esophageal Tube Feeding, interventions name: Nasogastric tube feeding, outcomesModule primaryOutcomes measure: Concentration of hemoglobin, primaryOutcomes measure: Concentration of albumin, primaryOutcomes measure: Concentration of prealbumin, primaryOutcomes measure: Nutritional status-body mass index, secondaryOutcomes measure: Decannulation of tracheostomy tube-placement duration, secondaryOutcomes measure: Decannulation of tracheostomy tube-Successful removal, secondaryOutcomes measure: Level of consciousness, secondaryOutcomes measure: Feeding Amount, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zheng Da yi Yuan Hospital, city: Zhengzhou, state: Henan, zip: 450000, country: China, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06261255, orgStudyIdInfo id: ATT_CS, briefTitle: Autotransplantation and Enamel Matrix Derivatives Case Series, acronym: ATTCS, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-06-01, primaryCompletionDateStruct date: 2023-09-01, completionDateStruct date: 2023-12-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Universidad Complutense de Madrid, class: OTHER, descriptionModule briefSummary: The goal of this prospective case series is to compare the adjunctive use of enamel matrix derivatives in the treatment of tooth autotransplantation in terms of clinical attachment level.The main question it aims to answer is:- What is the benefit, in terms of clinical attachment level, of using enamel matrix derivatives adjunctive to tooth autotransplantation?Participants will be subjected to a digitally protocol of tooth autotransplantation.Only one group (test) is assessed. It will be supplemented with the application of enamel matrix derivatives before the placement of the transplanted tooth into the surgically produced alveolus., conditionsModule conditions: Tooth Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This clinical investigation is a single-center, prospective case series study and is reported in compliance with the Preferred Reporting of Case Series in Surgery (PROCESS) guidelines. The study was conducted at the Department of Periodontology of the University Complutense of Madrid between March 2021 and September 2023., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ACTUAL, armsInterventionsModule interventions name: ATT + EMD, outcomesModule primaryOutcomes measure: Clinical attachment level (CAL), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universidad Complutense de Madrid, city: Madrid, zip: 28003, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, locations facility: Universidad Complutense Madrid, city: Madrid, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06261242, orgStudyIdInfo id: TWM-C-2201, briefTitle: Tripod-Fix Vertebral Body Augmentation System in Osteoporotic Vertebral Compression Fractures Treatment, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-16, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-07-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: National Cheng-Kung University Hospital, class: OTHER, descriptionModule briefSummary: This study is to evaluate the safety and effectiveness of the Tripod-Fix with Tecres Mendec® Spine HV System to treat subjects with osteoporotic vertebral compression fractures., conditionsModule conditions: Osteoporotic Vertebral Compression Fractures, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix), outcomesModule primaryOutcomes measure: Proportion of participants with study success, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cheng Kung University Hospital Department of Orthopedics, status: RECRUITING, city: Tainan, zip: 704, country: Taiwan, contacts name: Susan Guo, role: CONTACT, phone: +8666-2353535, phoneExt: 3690, contacts name: Cheng-Li Lin, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 22.99083, lon: 120.21333, hasResults: False
protocolSection identificationModule nctId: NCT06261216, orgStudyIdInfo id: 01/2023/LPA-wtATTR/NVNS, briefTitle: Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Medical University of Graz, class: OTHER, collaborators name: Medical University Innsbruck, descriptionModule briefSummary: The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy., conditionsModule conditions: Amyloid Cardiomyopathy, conditions: Wild Type ATTR Amyloidosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 252, type: ESTIMATED, armsInterventionsModule interventions name: Interview, outcomesModule primaryOutcomes measure: Association between lifetime physical activity and disease development, secondaryOutcomes measure: Association between lifetime athletic activity and disease development, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical University of Graz, status: RECRUITING, city: Graz, country: Austria, contacts name: PI, role: CONTACT, phone: 0043 316 385 30173, email: nicolas.verheyen@medunigraz.at, contacts name: Nicolas Verheyen, MD PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Nora Schwegel, MD, role: SUB_INVESTIGATOR, geoPoint lat: 47.06667, lon: 15.45, hasResults: False
protocolSection identificationModule nctId: NCT06261203, orgStudyIdInfo id: Hany Hosny, briefTitle: Low Dose Aspirin for Prevention of Early Pregnancy Loss, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2025-07-15, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Egymedicalpedia, class: INDUSTRY, descriptionModule briefSummary: Preeclampsia is a pregnancy-specific, multisystem disorder affecting 3% to 8% of pregnancies and remains a significant cause of maternal and neonatal morbidity and mortality worldwide.The World Health Organization estimates that approximately 76,000 maternal deaths annually are attributed to preeclampsia, accounting for 16% of global maternal mortality, with the majority occurring in low- and middle-income countries, conditionsModule conditions: Pre-Eclampsia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The The study's findings have the potential to clarify aspirin's role in preventing adverse pregnancy outcomes related to placental dysfunction and improve the management of women at risk of placental-mediated complications., primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Aspirin, outcomesModule primaryOutcomes measure: Prevention of pregnancy loss, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Assuit University hospitals, status: RECRUITING, city: Asyūţ, state: Assuit, country: Egypt, contacts name: Mohamed Nagy, Lecturer, role: CONTACT, phone: 01096655458, email: drmnagy@aun.edu.eg, contacts name: Abdelrahman Mahmoud, Assist.Prof., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06261190, orgStudyIdInfo id: H-2308-182-1463, briefTitle: Active Surveillance for Low-risk Papillary Thyroid Carcinoma, acronym: MAeSTroⅡ, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2029-12-31, completionDateStruct date: 2032-12-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: National Cancer Center, Korea, class: OTHER_GOV, collaborators name: Seoul National University Bundang Hospital, collaborators name: SMG-SNU Boramae Medical Center, collaborators name: Seoul National University Hospital, descriptionModule briefSummary: This study is an observational cohort study targeting patients with low-risk Papillary thyroid cancer who opted for active surveillance or immediate surgery based on a sufficient understanding of the treatment options. The primary objective of the study is to evaluate progression free survival of the patients with low-risk Papillary thyroid cancer who choose active surveillance, in other words, to observe the natural course of low-risk Papillary thyroid cancer., conditionsModule conditions: Thyroid Cancer, conditions: Papillary Thyroid Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 499, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Progression free survival of the patients with low-risk Papillary Thyroid Cancer who choose Active Surveillance, secondaryOutcomes measure: Disease progression, secondaryOutcomes measure: Rate of Participants in the Active Surveillance Group that change to surgery without disease progression, secondaryOutcomes measure: Comparison of Quality of Life between the Active Surveillance group and immediate surgery group, secondaryOutcomes measure: Measure of Anxiety and Depression, secondaryOutcomes measure: Measure of Satisfaction with the treatment, secondaryOutcomes measure: Factors influencing patients' decisions regarding disease management, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Center, city: Goyang-si, country: Korea, Republic of, contacts name: Eun Kyung Lee, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.65639, lon: 126.835, locations facility: Seoul National University Bundang Hospital, city: Seongnam, country: Korea, Republic of, contacts name: Jae Hoon Moon, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.43861, lon: 127.13778, locations facility: Seoul National University Hospital, city: Seoul, country: Korea, Republic of, contacts name: Young Joo Park, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.566, lon: 126.9784, locations facility: SMC-SNU Boramae Medical Center, city: Seoul, country: Korea, Republic of, contacts name: Ka Hi Lee, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06261177, orgStudyIdInfo id: 22-175, briefTitle: Take-home Functional Electrical Stimulation for MDD, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-12-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Unity Health Toronto, class: OTHER, descriptionModule briefSummary: The purpose of this study is to learn whether Functional Electrical Stimulation (FES) of the facial muscles is effective in treating major depressive disorder (MDD) and to develop a model for take-home delivery., conditionsModule conditions: MDD, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Double-blind, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Functional Electrical Stimulation (FES), interventions name: Sham FES, outcomesModule primaryOutcomes measure: Feasibility of the FES for MDD, primaryOutcomes measure: Tolerability and safety of the FES for MDD, secondaryOutcomes measure: Improvement in symptoms of depression-17-item Hamilton Depression Rating Scale (HAM-D-17), secondaryOutcomes measure: Improvement in symptoms of depression-16-Item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR-16), secondaryOutcomes measure: Improvement in symptoms of anxiety- General Anxiety Disorder (GAD-7), secondaryOutcomes measure: Improvement in well-being-World Health Organization-5 Well-Being Index (WHO-5), secondaryOutcomes measure: Improvement in sleep quality- Pittsburgh Sleep Quality Index (PSQI), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: St. Michael's Hospital, city: Toronto, state: Ontario, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False